Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Linda S. Steelman(East Carolina University), James A. McCubrey(East Carolina University), Franca Stivala(University of Catania), Christian Kempf(East Carolina University), Vivian Ruvolo(Hormel (United States)), Stephen L. Abrams(East Carolina University), Massimo Libra(University of Catania), Paolo Fagone(University of Catania), Jörg Bäsecke(University of Göttingen), Marco Donia(University of Copenhagen), Richard A. Franklin(Kamineni Institute of Dental Sciences), Alberto M. Martelli(University of Bologna), Peter P. Ruvolo(The University of Texas MD Anderson Cancer Center), Ferdinando Nicoletti(University of Catania), Camilla Evangelisti(University of Bologna), William H. Chappell(University of North Carolina at Chapel Hill)
Cited by 263
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508